Navidea Biopharmaceuticals Performance

NAVBDelisted Stock  USD 0.0001  0.00  0.00%   
Navidea Biopharmaceutica holds a performance score of 11 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 13.72, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Navidea Biopharmaceutica will likely underperform. Use Navidea Biopharmaceutica variance, as well as the relationship between the skewness and day typical price , to analyze future returns on Navidea Biopharmaceutica.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Navidea Biopharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Navidea Biopharmaceutica sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
  

Navidea Biopharmaceutica Relative Risk vs. Return Landscape

If you would invest  0.01  in Navidea Biopharmaceuticals on November 10, 2025 and sell it today you would earn a total of  0.00  from holding Navidea Biopharmaceuticals or generate 0.0% return on investment over 90 days. Navidea Biopharmaceuticals is currently generating 10.6667% in daily expected returns and assumes 74.9682% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Navidea, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Navidea Biopharmaceutica is expected to generate 92.27 times more return on investment than the market. However, the company is 92.27 times more volatile than its market benchmark. It trades about 0.14 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of risk.

Navidea Biopharmaceutica Target Price Odds to finish over Current Price

The tendency of Navidea Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.0001 90 days 0.0001 
about 58.22
Based on a normal probability distribution, the odds of Navidea Biopharmaceutica to move above the current price in 90 days from now is about 58.22 (This Navidea Biopharmaceuticals probability density function shows the probability of Navidea Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 13.72 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Navidea Biopharmaceutica will likely underperform. In addition to that Navidea Biopharmaceuticals has an alpha of 4.5027, implying that it can generate a 4.5 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Navidea Biopharmaceutica Price Density   
       Price  

Predictive Modules for Navidea Biopharmaceutica

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Navidea Biopharmaceutica. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Navidea Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.00009150.01
Details
Intrinsic
Valuation
LowRealHigh
0.000.00009550.01
Details

Navidea Biopharmaceutica Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Navidea Biopharmaceutica is not an exception. The market had few large corrections towards the Navidea Biopharmaceutica's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Navidea Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Navidea Biopharmaceutica within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
4.50
β
Beta against Dow Jones13.72
σ
Overall volatility
0.000053
Ir
Information ratio 0.11

Navidea Biopharmaceutica Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Navidea Biopharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Navidea Biopharmaceutica can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Navidea Biopharmaceutica is not yet fully synchronised with the market data
Navidea Biopharmaceutica is way too risky over 90 days horizon
Navidea Biopharmaceutica has some characteristics of a very speculative penny stock
Navidea Biopharmaceutica appears to be risky and price may revert if volatility continues
Navidea Biopharmaceutica has a very high chance of going through financial distress in the upcoming years
Navidea Biopharmaceuticals currently holds 2.43 M in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Navidea Biopharmaceutica has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Navidea Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Navidea Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Navidea Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Navidea to invest in growth at high rates of return. When we think about Navidea Biopharmaceutica's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 65.65 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (119.3 K).
Navidea Biopharmaceuticals currently holds about 328.01 K in cash with (8.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 35.0% of Navidea Biopharmaceutica outstanding shares are owned by corporate insiders

Navidea Biopharmaceutica Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Navidea Pink Sheet often depends not only on the future outlook of the current and potential Navidea Biopharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Navidea Biopharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding29.3 M
Cash And Short Term InvestmentsM

Navidea Biopharmaceutica Fundamentals Growth

Navidea Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Navidea Biopharmaceutica, and Navidea Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Navidea Pink Sheet performance.

About Navidea Biopharmaceutica Performance

By analyzing Navidea Biopharmaceutica's fundamental ratios, stakeholders can gain valuable insights into Navidea Biopharmaceutica's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Navidea Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Navidea Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio. Navidea Biopharmaceutica operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 11 people.

Things to note about Navidea Biopharmaceutica performance evaluation

Checking the ongoing alerts about Navidea Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Navidea Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Navidea Biopharmaceutica is not yet fully synchronised with the market data
Navidea Biopharmaceutica is way too risky over 90 days horizon
Navidea Biopharmaceutica has some characteristics of a very speculative penny stock
Navidea Biopharmaceutica appears to be risky and price may revert if volatility continues
Navidea Biopharmaceutica has a very high chance of going through financial distress in the upcoming years
Navidea Biopharmaceuticals currently holds 2.43 M in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Navidea Biopharmaceutica has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Navidea Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Navidea Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Navidea Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Navidea to invest in growth at high rates of return. When we think about Navidea Biopharmaceutica's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 65.65 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (119.3 K).
Navidea Biopharmaceuticals currently holds about 328.01 K in cash with (8.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 35.0% of Navidea Biopharmaceutica outstanding shares are owned by corporate insiders
Evaluating Navidea Biopharmaceutica's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Navidea Biopharmaceutica's pink sheet performance include:
  • Analyzing Navidea Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Navidea Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
  • Examining Navidea Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Navidea Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Navidea Biopharmaceutica's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Navidea Biopharmaceutica's pink sheet. These opinions can provide insight into Navidea Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Navidea Biopharmaceutica's pink sheet performance is not an exact science, and many factors can impact Navidea Biopharmaceutica's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Consideration for investing in Navidea Pink Sheet

If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation